| Document |
Document Title |
|
WO/2023/113457A1 |
The present invention relates to a compound capable of degrading a target protein by using ubiquitination, and provides a compound having a targeted protein binding moiety (TBM) structure, which binds to a target protein or polypeptide, ...
|
|
WO/2023/112939A1 |
A method for purifying a composition that comprises a step for dissolving the composition containing a compound represented by formula(1) [in formula (1): R1 represents -N(R2)-R2 (wherein R2 represents a C1-C4 alkyl group); R3 and R4 rep...
|
|
WO/2023/114188A1 |
Provided herein are compounds, such as compounds of Formula (I), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, and isotopically labeled derivatives thereof, and compositions...
|
|
WO/2023/103734A1 |
Disclosed in the present invention are a cannabidiol derivative, a preparation method therefor and an application thereof, particularly an application in preventing and treating nervous system diseases (such as Parkinson's disease). The ...
|
|
WO/2023/103733A1 |
Disclosed are a cannabidiol derivative, and a preparation method therefor and the use thereof, and in particular the use thereof in the prevention and treatment of a nervous system disease (such as epilepsy and Parkinson's disease). The ...
|
|
WO/2023/098670A1 |
Disclosed are a polyphenol antioxidant and a preparation method therefor and an application thereof. An antioxidant molecule designed in the present invention contains a hindered phenol functional group used as a main antioxidant, and fu...
|
|
WO/2023/083983A1 |
The present invention thus provides a novel family of liposomal compositions (nanocarriers), hereinafter referred to as Tetra-Acidosomes, comprising natural tetrameric acid (TA) lipids and/or novel chemically functionalized tetrameric ac...
|
|
WO/2023/083291A1 |
The present invention relates to compounds of formula I and formula II and the use thereof in the treatment of metabolic diseases such as liver fibrosis and non-alcoholic hepatitis. Specifically, provided are the compounds as shown, and ...
|
|
WO/2023/061460A1 |
Provided is a novel cationic lipid having a structure as represented in general formula (1), which specifically relates to a nitrogen-containing cationic lipid, and also relates to a liposome containing the cationic lipid, a liposome pha...
|
|
WO/2023/061999A1 |
The present invention discloses a distinct mode of action of a nickel catalyst to forge C-0 bonds to unlock the mild utilization of N2O as O-atom transfer reagent in the synthesis of complex phenols from the corresponding aryl halides.
|
|
WO/2023/056917A1 |
Provided herein are lipid compounds that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nuc...
|
|
WO/2023/045377A1 |
The present invention relates to a novel deuterated PEG lipid compound, a preparation method therefor, and a composition and an application thereof. Specifically disclosed are a novel deuterated lipid compound as shown in formula A and f...
|
|
WO/2023/042081A1 |
The invention relates to a process to produce a (1r,4r)-4-substituted cyclohexane-1-amine [further referred as trans-4-substituted cyclohexane-1-amine] of formula (T), starting from a diastereomeric mixture of 4-substituted cyclohexane-1...
|
|
WO/2023/044343A1 |
The present disclosure details various lipids, compositions, and/or methods of optimized systems and delivery vehicles for the delivery of nucleic acid sequences, polypeptides or peptides for use in vaccinating against infectious agents.
|
|
WO/2023/043038A1 |
The present invention provides a novel compound for a capping layer, and an organic light-emitting device comprising same.
|
|
WO/2023/035652A1 |
The present invention relates to a lipid compound having the structure of the following formula I, or a salt thereof, or an isomer thereof, or an N-oxide thereof, capable of being used alone or in combination with other lipid components,...
|
|
WO/2023/031210A1 |
The present application generally relates to stereochemically pure lipids that can be used, also in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles w...
|
|
WO/2023/024514A1 |
The present invention relates to a lipid compound, which can be used alone or in combination with other lipid components such as neutral lipids, spotted lipids and steroids and/or analogs thereof, and/or polymer-conjugated lipids, so as ...
|
|
WO/2023/024513A1 |
The present invention relates to a lipid compound, which can be used alone or in combination with other lipid components such as neutral lipids, charged lipids, steroids, and/or analogs thereof, and/or polymer conjugated lipids, so as to...
|
|
WO/2023/024512A1 |
The present invention relates to a lipid compound that can be used alone or in combination with other lipid components such as neutral lipids, spotted lipids, steroids and/or analogs thereof, and/or polymer-conjugated lipids, to form lip...
|
|
WO/2023/022155A1 |
The present invention provides a polymer-dispersed liquid crystal element which is provided with a liquid crystal alignment film that achieves high adhesion between a polymer liquid crystal layer and a base material, while having a high ...
|
|
WO/2023/017527A1 |
The present invention relates to an additive comprising stearic acid and ethanolamine. The invention also relates to a process for the preparation of said additive. The present additive significantly improves the silica filler dispersion...
|
|
WO/2023/015904A1 |
The present invention relates to a lipid compound, which can be used alone, or can be used in combination with other lipid components such as neutral lipids, charged lipids, steroids and/or analogues thereof, and/or polymer-conjugated li...
|
|
WO/2023/005971A1 |
A use of one or more lipid compounds in the delivery of nucleic acids, and a lipid nucleic acid mixture, pharmaceutical composition or kit comprising the lipid compounds and nucleic acids. The lipid compounds provided above can promote t...
|
|
WO/2023/287067A1 |
The present invention relates to a novel compound and, more specifically, to a compound exhibiting excellent antibacterial properties, and enabling the preparation of a polymer that has a polymerizable functional group so as to exhibit a...
|
|
WO/2023/279836A1 |
Provided are an ionizable lipid compound of formula I for nucleic acid delivery and an LNP composition thereof, which can efficiently and stably deliver a biologically active substance to a target cell or an organ. The mRNA LNP prepared ...
|
|
WO/2023/281077A1 |
The present invention relates to a method for obtaining dimethylaminoethyl (meth)acrylate comprising reacting a (meth)acrylic ester with dimethylaminoethanol that is at least partially renewable and non-fossil.
|
|
WO/2022/269041A1 |
The present invention is directed to a method for continuous production of cationic lipids. Said cationic lipids are particularly useful in combination with other lipid components for forming lipid nanoparticles with oligonucleotides (e....
|
|
WO/2022/247755A1 |
Provided herein are lipid compounds that can be used in combination with other lipid components, such as neutral lipids, cholesterol andpolymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucl...
|
|
WO/2022/235726A1 |
(R)-Oxybutynin D-malate salts, including crystalline and amorphous forms, are prepared and characterized. Uses of (R)-oxybutynin D-malate for obstructive sleep apnea (OSA) treatment are also disclosed. Solid forms of (R)-oxybutynin L-tar...
|
|
WO/2022/233291A1 |
The invention provides a lipid of Formula (I) and nanoparticle compositions containing the same. Nanoparticle compositions including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylact...
|
|
WO/2022/230964A1 |
The present invention addresses the problem of providing: a compound or a salt thereof which constitutes lipid particles that make it possible to achieve a high nucleic acid encapsulation rate and excellent nucleic acid delivery; and lip...
|
|
WO/2022/225427A1 |
The invention relates to the field of organic chemistry and pharmaceutics and concerns novel compounds of [2-(dimethylamino)-2-phenylbutyl]-3,4,5-trimethoxybenzoate of general structural formula I; a method for the treatment or prophylax...
|
|
WO/2022/214025A1 |
Disclosed in the present invention are a pegylated lipid, a preparation method therefor, a liposome containing the pegylated lipid, a pharmaceutical composition containing the liposome, a preparation thereof, and the use thereof, belongi...
|
|
WO/2022/213895A1 |
The present invention provides a novel cationic lipid having a structure as shown in general formula (1) and particularly relates to a nitrogen-branched cationic lipid, and also relates to a liposome containing the cationic lipid, and a ...
|
|
WO/2022/214026A1 |
Disclosed in the present invention are a pegylated lipid and a preparation method therefor, a liposome comprising the pegylated lipid, and a pharmaceutical composition comprising the liposome and a preparation and use thereof, relating t...
|
|
WO/2022/213931A1 |
A prodrug of cannabidiol, a preparation method therefor, and a pharmaceutical composition thereof. The present invention further relates to a use of a compound or pharmaceutical composition containing the prodrug in preparation of drugs ...
|
|
WO/2022/215002A1 |
The present disclosure provides methods for producing a compound having a chemical formula of Formula I, wherein R1 and R2 are independently a i) linear or branched or cyclic, ii) saturated or unsaturated, and iii) substituted or unsubst...
|
|
WO/2022/207230A1 |
A fabric conditioner composition comprising: a) Fabric softening active according to formula (I), wherein each R, is independently selected from C5-C27 aliphatic groups, Y is a divalent C1-C6 aliphatic group, R', R'' and R''', are indepe...
|
|
WO/2022/153187A1 |
Methods for producing a compound of Formula I, Formula I, wherein R1 and R2 are independently a i) linear or branched or cyclic, ii) saturated or unsaturated, and iii) substituted or unsubstituted hydrocarbon group comprising 8 to 20 car...
|
|
WO/2022/152109A2 |
Provided herein are lipid compounds that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nuc...
|
|
WO/2022/148655A1 |
A fabric conditioner composition comprising; a) Ester linked quaternary ammonium compounds; and b) 0.1 to 30 wt.% perfume materials; wherein the ester linked quaternary 5 ammonium compounds comprise carbon chains derived from fatty acids...
|
|
WO/2022/148673A1 |
Esterquats find major applications as fabric softeners. After Tallow fatty acids and Palm oil fatty acids, fatty acids from sustainable sources like Rice bran fatty acids (RBFA) are desired. RBFA is formed as a by-product during refining...
|
|
WO/2022/121317A1 |
Disclosed is a 1,1'-biphenyl-2,6-diphenolic compound and the use thereof. The 1,1'-biphenyl-2,6-diphenolic compound is a new compound, and has good biological activity. By means of in vitro tumor cell activity experiments, it was found t...
|
|
WO/2022/076507A1 |
The present disclosure relates to compounds that are capable of inhibiting PRMT8 and/or upregulating SirTl. The disclosure further relates to methods of treating neurodegenerative diseases and disorders (e.g., Alzheimer's disease).
|
|
WO/2022/067446A1 |
Disclosed is a proteolipid vesicle (PLV) for delivering a therapeutic cargo, such as nucleic acids, polypeptides and molecules, to a cell, the proteolipid vesicle having a lipid nanoparticle comprising one or more ionizable lipids and on...
|
|
WO/2022/063350A1 |
The subject of the present invention is a lipidoid of general formula (I), wherein X, Y, Z and R are as defined in the claims. This lipidoid is useful as a transfection agent. The invention further describes transfection agents, transfec...
|
|
WO/2022/055267A1 |
The present specification relates to a method for preparing alkyl-D-alaninate, the method comprising a step for supplying an inert gas into a reaction solution when using aniline to synthesize alkyl-D-alaninate.
|
|
WO/2022/015604A1 |
Personal care products, such as shampoos, conditioners, hair dyes, hair removal products, cleansers, cosmetics, mascaras, and toothpastes may be formulated to include one or more branched surfactants, from one or more surfactant classes,...
|
|
WO/2021/244637A1 |
Provided herein is 2-(diethylamino) ethyl 2-(4-isobutylphenyl) propionate or pharmaceutically acceptable salts thereof. Furthermore, for use and methods in the treatment of various pains and inflammation, in particular osteoarthritis wit...
|
